Phase 3 clinical trials have confirmed that higher weekly doses of semaglutide (7.2 mg) safely deliver greater weight loss and improved metabolic health outcomes in adults with obesity, regardless of type 2 diabetes status. These pivotal studies may influence clinical practice and inform dosing strategies for this leading GLP-1 receptor agonist amid growing obesity management needs.